Drugs / tumor-draining lymph node lymphocyte therapy
tumor-draining lymph node lymphocyte therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003185 | Aug 1997 → Jul 1998 | central nervous system neoplasm | The Cleveland Clinic | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor-draining lymph node lymphocyte therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003185 ↗ |
| Modality | Cell therapy | “Adoptive immunotherapy, the transfer of immune T lymphocytes, is capable of mediating the regression of experimental brain tumors in animal models.” PMID 9647171 ↗ Jul 1998 |
| Route | Intravenous | “These cells were given to patients by intravenous infusion at doses ranging from 9 x 10(8) to 1.5 x 10(11).” PMID 9647171 ↗ Jul 1998 |